Maplight Therapeutics holder plans 48,158-share stock sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Maplight Therapeutics, Inc. has a planned sale of 48,158 common shares of its stock through Jefferies LLC, with an indicated sale date of July 15, 2026 on NASDAQ. The shares have an aggregate market value of $1,825,669.78, while 42,620,000 shares are outstanding. The seller, Erin Pennock Foff, acquired Maplight shares via restricted stock unit grants on several dates and has already sold multiple blocks of shares between April 15 and May 7, 2026, including 24,052 shares on May 6, 2026 for $691,814.17.
Key Figures
Key Terms
Form 144 regulatory
restricted stock unit financial
aggregate market value financial
Securities To Be Sold regulatory
Securities Sold During The Past 3 Months regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.